TetraLogic Pharmaceuticals develops Birinapant, a small‑molecule therapeutic that neutralizes inhibitors of apoptosis proteins to trigger caspase‑mediated tumor cell death. Birinapant has produced tumor regression as a single agent and shows potent anti‑tumor activity in preclinical studies when combined with chemotherapies and death receptor ligands. The drug is being evaluated across multiple clinical programs, including Phase 1, Phase 1b and Phase 2 trials, with a Phase 2 study in ovarian cancer and combination studies with Gemcitabine, FOLFIRI, Bevacizumab and a Phase 2a study with Irinotecan. The company is based in Malvern, Pennsylvania. TetraLogic recently completed a $5 million financing in the form of debt, options and warrants to advance its clinical programs; this follows a $6 million raise last year and a $32 million Series C in October 2010. TetraLogic Pharmaceuticals is a Malvern, PA-based biopharmaceutical company developing novel small-molecule drugs to treat cancer. Its lead candidate, TL32711, is a SMAC mimetic that neutralizes inhibitor of apoptosis proteins (IAPs) that block tumor cell death. TL32711 is being evaluated in a Phase 1 study as a single agent in patients with solid tumors and lymphoma refractory to standard therapies. The company received additional funding to advance clinical development of TL32711. The new funds increased the company's Series C financing to $37M following a $5M investment from Pfizer Ventures. TetraLogic had previously announced an initial Series C closing of $32M on August 10, 2010, led by Clarus Ventures with participation from Hatteras Venture Partners and other investors.

Total raised

$10M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Dec 2012